Glenmark Pharma Q3 Profit Soars 15.9%, Revenue Up 15.1% Driven by India, North America

• Glenmark Pharmaceuticals reported a 15.9% year-on-year increase in net profit to ₹403 crore for Q3 FY25.
• Revenue grew by 15.1% to ₹3,900 crore, with EBITDA surging 45% to ₹868.7 crore.
• India formulations revenue rose 22.1% to ₹12,986 million, while North America revenue climbed 24.2% to ₹9,706 million.
• Europe and Emerging Markets also showed steady growth, increasing by 9.1% and 8.4% respectively.
• Chairman Glenn Saldanha highlighted strong performance of innovation portfolio, including RYALTRIS® and WINLEVI®.

Why It Matters: Glenmark Pharma delivered strong Q3 results with significant profit and revenue growth driven by key markets.